Natixis Buys Shares of 79,900 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Natixis acquired a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 79,900 shares of the company's stock, valued at approximately $645,000. Natixis owned approximately 0.11% of ORIC Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in ORIC Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock worth $5,788,000 after acquiring an additional 103,237 shares in the last quarter. XTX Topco Ltd boosted its stake in ORIC Pharmaceuticals by 120.9% in the 4th quarter. XTX Topco Ltd now owns 25,966 shares of the company's stock worth $210,000 after purchasing an additional 14,209 shares in the last quarter. Barclays PLC grew its position in ORIC Pharmaceuticals by 6.9% during the 4th quarter. Barclays PLC now owns 114,692 shares of the company's stock worth $927,000 after purchasing an additional 7,431 shares during the last quarter. Invesco Ltd. increased its position in shares of ORIC Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after acquiring an additional 1,876 shares during the period. Finally, Wells Fargo & Company MN raised its stake in ORIC Pharmaceuticals by 30.2% in the 4th quarter. Wells Fargo & Company MN now owns 35,857 shares of the company's stock worth $289,000 after acquiring an additional 8,311 shares during the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Stock Down 0.1 %

NASDAQ:ORIC traded down $0.01 on Monday, reaching $5.10. 303,461 shares of the company's stock were exchanged, compared to its average volume of 634,268. The firm has a market capitalization of $361.88 million, a price-to-earnings ratio of -2.80 and a beta of 1.38. ORIC Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The business has a fifty day moving average of $6.39 and a 200-day moving average of $8.33.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.01. As a group, equities analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ORIC has been the topic of several research reports. Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Wedbush reaffirmed an "outperform" rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. JPMorgan Chase & Co. lifted their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $18.86.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.